Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention
Randomized Comparison of an Ultra-low Strut Thickness Everolimus-eluting Biodegradable Polymer Stent Versus Durable Polymer Everolimus-eluting Stents in Patients Treated with Percutaneous Coronary Intervention in an All Comer Population (The SORT OUT XII Trial)
Odense University Hospital
3,150 participants
Nov 16, 2024
INTERVENTIONAL
Conditions
Summary
The objective of this randomized study is to compare the safety and efficacy of the ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent to the everolimus-eluting family stents (durable polymer everolimus-eluting Xience or Promus stents) in a population-based setting with coronary artery stenosis treated with percutaneous coronary intervention
Eligibility
Inclusion Criteria1
- All patients aged ≥18 years who are eligible for treatment with one or several drug-eluting coronary stents
Exclusion Criteria7
- Age \< 18 years
- Not able to consent to study participating (eg. intubated patients)
- Unstable circuit or in cardiogenic shock and therefore not able to understand the information and purpose of the study
- Do not speak Danish
- Already included in the SORT OUT XII study
- Life expectancy \<1 year
- Allergic to study related treatment
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Percutaneous coronary intervention with Ultra-low strut thickness everolimus-eluting biodegradable polymer Evermine50 stent(s)
Percutaneous coronary intervention with Everolimus-eluting stents (durable polymer everolimus-eluting Xience or Promus stent(s))
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06692140